Exomira Medicine Inc.

Exomira Medicine Inc., a for-profit small business joint venture based in Chicago, Illinois, operates as a sub-recipient on federal biomedical research grants, delivering clinical analysis and therapeutic development services under subawards from Northwestern University. The vendor has no prime contract or prime grant footprint; all four recent awards are sub-recipient positions funded through NIH grant programs.

Exomira's customer concentration, by design, is entirely within the National Institutes of Health. The National Institute of Allergy and Infectious Diseases (NIAID) funds three of four recent sub-awards, all centered on clinical analysis and therapeutic development of exosomal ACE2, with the most recent delivery occurring in March 2026. The National Cancer Institute funds one sub-award for development of a novel dual-efficacy immunotherapy targeting triple-negative breast cancer. All sub-recipient work flows through Northwestern University as the prime grant recipient.

Activity has been steady at one sub-award per year across 2023 through 2026, with combined dollars obligated across all four awards totaling $556 thousand. The vendor's entire federal footprint consists of NIH basic and translational research subawards, with no vehicle positions, no prime relationships, and no direct federal customer engagement. Exomira's capability profile, as evidenced by sub-recipient work, centers on exosomal therapeutic development and breast cancer immunotherapy, positioned within Northwestern University's broader NIH-funded research portfolio rather than as an independent federal contractor or recipient.